GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
GSK RSV shot 43% effective against severe disease in third year
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the shot.
GSK: Does RSV jab work too well?
GSK PLC's respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by Jefferies. The jab is designed to protect older adults from RSV, a common virus that can lead to severe respiratory infections.
Why GSK (GSK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.
GSK settles two California lawsuits related to heartburn drug Zantac
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK cancer drugs fast-tracked by Chinese
GSK PLC (LSE:GSK, NYSE:GSK) announced that its blood cancer drug Blenrep (belantamab mafodotin), in combination with two current treatments, has received Breakthrough Therapy Designation (BTD) in China. This award, granted by the National Medical Products Administration (NMPA), is aimed at speeding up the development of treatments for serious diseases that show promise in improving patient outcomes over current options.
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's proprietary second-generation mRNA backbone GSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a significant milestone payment for CureVac In July 2024, GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that GSK has reported positive Phase 2 headline data from the seasonal influenza mRNA vaccine program.
GSK enjoys success with mRNA flu vaccine trial
GSK PLC (LSE:GSK, NYSE:GSK) has been encouraged by the initial results of a seasonal flu vaccine using mRNA technology. Following disappointing tests for its vaccine division earlier in the week with trials of an experimental herpes treatment, the FTSE 100 pharmaceutical group said a phase II influenza vaccine has shown enough positive effects to be moved to final phase III trials.
GSK's mRNA flu vaccine programme to proceed to late-stage trials
British drugmaker GSK on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progress to late-stage clinical development.
